BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20808813)

  • 21. Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes.
    Veres G; Escaich S; Baker J; Barske C; Kalfoglou C; Ilves H; Kaneshima H; Böhnlein E
    J Virol; 1996 Dec; 70(12):8792-800. PubMed ID: 8971008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication.
    Veres G; Junker U; Baker J; Barske C; Kalfoglou C; Ilves H; Escaich S; Kaneshima H; Böhnlein E
    J Virol; 1998 Mar; 72(3):1894-901. PubMed ID: 9499041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.
    Humeau LM; Binder GK; Lu X; Slepushkin V; Merling R; Echeagaray P; Pereira M; Slepushkina T; Barnett S; Dropulic LK; Carroll R; Levine BL; June CH; Dropulic B
    Mol Ther; 2004 Jun; 9(6):902-13. PubMed ID: 15194057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
    Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
    J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1.
    Chang HK; Gendelman R; Lisziewicz J; Gallo RC; Ensoli B
    Gene Ther; 1994 May; 1(3):208-16. PubMed ID: 7584083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained inhibition of HIV-1 replication by conditional expression of the E. coli-derived endoribonuclease MazF in CD4+ T cells.
    Okamoto M; Chono H; Kawano Y; Saito N; Tsuda H; Inoue K; Kato I; Mineno J; Baba M
    Hum Gene Ther Methods; 2013 Apr; 24(2):94-103. PubMed ID: 23442049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
    Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
    Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication.
    Taylor JA; Vojtech L; Bahner I; Kohn DB; Laer DV; Russell DW; Richard RE
    Mol Ther; 2008 Jan; 16(1):46-51. PubMed ID: 17955023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer.
    Li Y; Starr SE; Lisziewicz J; Ho WZ
    Gene Ther; 2000 Feb; 7(4):321-8. PubMed ID: 10694813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines.
    Lisziewicz J; Sun D; Gallo RC; Ensoli B; Lori F
    Hum Gene Ther; 1996 Dec; 7(18):2209-16. PubMed ID: 8953311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes.
    VandenDriessche T; Chuah MK; Chiang L; Chang HK; Ensoli B; Morgan RA
    J Virol; 1995 Jul; 69(7):4045-52. PubMed ID: 7769662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
    Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
    Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
    Lee SW; Gallardo HF; Gilboa E; Smith C
    J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
    BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
    J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat.
    Poznansky MC; La Vecchio J; Silva-Arietta S; Porter-Brooks J; Brody K; Olszak IT; Adams GB; Ramstedt U; Marasco WA; Scadden DT
    Hum Gene Ther; 1999 Oct; 10(15):2505-14. PubMed ID: 10543615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitat gene therapy: a candidate for late-stage AIDS patients.
    Lisziewicz J; Sun D; Lisziewicz A; Gallo RC
    Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells.
    Neumann T; Hagmann I; Lohrengel S; Heil ML; Derdeyn CA; Kräusslich HG; Dittmar MT
    Virology; 2005 Mar; 333(2):251-62. PubMed ID: 15721359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat.
    Braun SE; Taube R; Zhu Q; Wong FE; Murakami A; Kamau E; Dwyer M; Qiu G; Daigle J; Carville A; Johnson RP; Marasco WA
    Hum Gene Ther; 2012 Sep; 23(9):917-31. PubMed ID: 22734618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry.
    Esposito AM; Cheung P; Swartz TH; Li H; Tsibane T; Durham ND; Basler CF; Felsenfeld DP; Chen BK
    Virology; 2016 Mar; 490():6-16. PubMed ID: 26803470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.